Maternal serum insulin-like growth factor-I at 11-13 weeks in preeclampsia.

09:16 EDT 31st August 2015 | BioPortfolio

Summary of "Maternal serum insulin-like growth factor-I at 11-13 weeks in preeclampsia."


OBJECTIVE:
To investigate the maternal serum concentration of insulin-like growth factor-I (IGF-I) in the first trimester of pregnancies that subsequently develop preeclampsia (PE) and to examine the possible association with uterine artery pulsatility index (PI).
METHODS:
The maternal serum concentration of IGF-I and uterine artery PI at 11-13 weeks were measured in 53 cases that developed PE, including 18 that required delivery before 34 weeks (early-PE) and 106 unaffected controls. The measured IGF-I concentration and uterine artery PI were converted into a multiple of the expected median (MoM) in unaffected pregnancies, and median MoM values were compared in the outcome groups. The significance of association of IGF-I MoM with uterine artery PI MoM was determined by regression analysis.
RESULTS:
In the early-PE and late-PE groups, compared to the unaffected controls, the median IGF-I decreased (0.53 and 0.55 MoM, respectively) and uterine artery PI increased (1.55 and 1.21 MoM, respectively). In the group that developed PE, there was no significant association between serum IGF-I and uterine artery PI (p = 0.632).
CONCLUSION:
In pregnancies destined to develop PE, the circulating levels of IGF-I decrease from the first trimester of pregnancy suggesting that IGF-I may be implicated in the pathogenesis of the disease. Copyright © 2010 John Wiley & Sons, Ltd.

Affiliation

Department of Obstetrics and Gynaecology, University Hospital of Heraklion, Crete, Greece.

Journal Details

This article was published in the following journal.

Name: Prenatal diagnosis
ISSN: 1097-0223
Pages:

Links

PubMed Articles [23047 Associated PubMed Articles listed on BioPortfolio]

First-Trimester Maternal Serum Levels of sFLT1, PGF and ADMA Predict Preeclampsia.

Placental growth factor (PGF), soluble fms-like tyrosine kinase 1 (sFLT1) and asymmetric dimethylarginine (ADMA) are involved in the pathogenesis of preeclampsia. Abnormal maternal sFLT1, PGF and ADMA...

Does endurance training affect igf-1/igfbp-3 and insulin sensitivity in patients with type 2 diabetes?

The aim of the present study was to determine whether six weeks of sub maximal endurance training using a cycle ergometer would result in a modified serum insulin--like growth factor--1(IGF--1),an ins...

Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks.

To investigate the potential value of maternal serum placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) at 35-37 weeks' gestation in the prediction of delivery of small for...

Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30-34 weeks.

To investigate the potential value of combined screening by maternal characteristics and medical history (maternal factors), estimated fetal weight (EFW), uterine artery pulsatility index (PI), mean a...

Placental fibroblast growth factor 21 is not altered in late-onset preeclampsia.

Preeclampsia (PE) is associated with alterations of placental function. The incidence of PE is higher in insulin resistant states. Women with PE have high circulating levels of the metabolic regulator...

Clinical Trials [6288 Associated Clinical Trials listed on BioPortfolio]

PP13 and Doppler Study to Predict Preeclampsia

Assessment of biochemical and sonographic marker to predict the risk for developing preeclampsia Among biochemical markers are serum level of Placental Protein 13 (PP13) and Placenta Growt...

Is Serum YKL-40 Capable of Predicting Intrauterine Growth Restriction (IUGR) and Preeclampsia?

Objective: To investigate the role of maternal serum YKL-40 and uterine artery doppler, at gestational age 12, 20, 25 and 32 weeks, and the relation to preeclampsia and intrauterine growth...

LMWH to Prevent Preeclampsia and Fetal Growth Restriction

The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin ...

Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia

Preeclampsia (PE) complicates 2-8% of pregnancies. It is associated with an increased risk of adverse maternal (death, eclampsia, abruptio placenta, HELLP syndrome) and perinatal (perinata...

Alterations in the Plasma Proteome of Early-Onset Severe Preeclampsia

The hypothesis of this study is that many plasma proteins are altered in concentration and structure in preeclampsia and the elucidation of these alterations will add to the poorly underst...

Medical and Biotech [MESH] Definitions

A well-characterized neutral peptide believed to be secreted by the LIVER and to circulate in the BLOOD. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on SOMATOTROPIN. It is believed to be a major fetal growth factor in contrast to INSULIN-LIKE GROWTH FACTOR I, which is a major growth factor in adults.

A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor.

A blood protein (NSILA) which mimics the biological activity of insulin in serum, but is not suppressed by insulin antibodies. During acid-ethanol extraction of Cohn fraction III, 10% of the activity is found in the supernatant (NSILA-S) and the remaining activity in the precipitate (NSILA-P). The latter is a large molecular compound, much less stable than the soluble fraction. NSILA-S is a more potent growth factor than insulin and exhibits sulfation activity.

One of the six homologous soluble proteins that bind insulin-like growth factors (SOMATOMEDINS) and modulate their mitogenic and metabolic actions at the cellular level.

One of the six homologous soluble proteins that bind insulin-like growth factors (SOMATOMEDINS) and modulate their mitogenic and metabolic actions at the cellular level.


Advertisement
 

Relevant Topic

Women's Health
Latest News Clinical Trials Research Drugs Reports Corporate
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Advertisement
 

Searches Linking to this Article